BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in orphan and infectious diseases, with the goal of addressing unmet medical needs of patients and physicians.
BioCryst's core development programs include BCX7353 and additional 2nd generation oral inhibitors of plasma kallikrein for hereditary angioedema; and BCX4430 (GALIDESIVIR), a broad spectrum antiviral for hemorrhagic fevers. BioCryst’s discovery team is also designing drug candidates against two undisclosed rare disease targets.
In December 2014, RAPIVAB® (peramivir injection) was approved by the FDA, the first FDA approval of a BioCryst Pharmaceuticals discovered drug.
In June 2015, BioCryst entered into a license agreement with bioCSL (now Seqirus) to manufacture and commercialize RAPIVAB for the treatment of influenza worldwide, except for the rights to conduct such activities in Israel, Japan, Korea and Taiwan.
1 Peramivir injection is approved in Japan and Taiwan, and is marketed by Shionogi & Co., Ltd. under the commercial name RAPIACTA® for the treatment of adults, children and infants with influenza
2 Peramivir injection is approved in Korea and is marketed by Green Cross Corporation under the commercial name under the commercial name PeramiFlu®